Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy

EuroIntervention 2016;12:798-800. DOI: 10.4244/EIJV12I6A129

Giulio Stefanini
Giulio G. Stefanini1*, MD, PhD; Miles Behan2, MD; Marco Valgimigli3, MD, PhD; Keith G. Oldroyd4, MD; Martin B. Leon5, MD
1. Cardio Center, Humanitas Research Hospital, Rozzano - Milan, Italy; 2. Edinburgh Heart Centre, Royal Infirmary of Edinburgh and Roodlands Hospital, Haddington, United Kingdom; 3. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 4.

Introduction to the session

The aim of the article is to capture the session at EuroPCR 2016, communicate the analysis of the trialist, and report the views expressed in the interactive discussion. The article does not constitute an independent review of the topic by the authors. The session focused on whether the LEADERS-FREE randomised trial will change clinical practice1.

Background: what was known before LEADERS-FREE

A large body of evidence consistently proved superiority of drug-eluting stents (DES) over bare metal stents (BMS) in terms of antirestenotic effectiveness2. In 2006, early-generation DES were associated with an increased risk of ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Coronary interventionsStents and scaffoldsTools, devices and techniques
Read next article
Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease

Latest news